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ABSTRACT 
IN VIVO INVESTIGATIONS OF POLYMER  
CONJUGATES AS THERAPEUTICS 
SEPTEMBER 2011 
ELIZABETH M. HENCHEY  
B.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Sallie Smith Schneider 
Polymer conjugates offer a way to introduce materials into the body that would 
normally be rejected or cause toxicity. Two polymers are investigated in vivo for uses 
in chemotherapeutic delivery, protein therapeutics, and DNA transfection. A novel 
polymer, polyMPC, has the ability to increase doxorubicin loading and its solubility, 
and is conjugated in a way to release its payload in a low pH environment. Through 
its conjugation, blood clearance time of doxorubicin is increased, and thus tumor 
exposure to the drug is increased with a single administration. It can be administered 
at ten times the concentration of free doxorubicin, and three times the concentration of 
Doxil®, while decreasing the cardio-toxicity normally associated with doxorubicin 
administration. These results show that polyMPC has the potential to increase 
treatment efficacy of doxorubicin. With increased circulation time, MPC polymers 
have additional potential for protein delivery and variations of its design were tested 
in linear, branched and grafted states, which show limited affect on tissue weight. An 
additional polymer for use in DNA transfection, NLS2, demonstrated its lack of tissue 
toxicity when injected intramuscularly. While continued investigation into these 
polymers is required, this initial data indicates their promising uses as therapeutics.
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CHAPTER 1 
INTRODUCTION 
 
Current chemotherapeutic cancer treatment options are accompanied by adverse side 
effects that reduce the administrable drug concentration and thus the chances for a 
successful treatment response.  Prodrugs are nanosized, polymer-drug conjugates that 
offer a way to increase drug dosage concentrations. They prevent toxicity of the drug 
by releasing it from the polymer following hydrolysis or enzymolysis at the drug to 
polymer linkage point (Kratz et al. 2008). Polymers can increase a drug's 
hydrodynamic size, which allows longer circulation time in the blood stream and 
greater drug accumulation in the tumor environment through the enhanced permeation 
and retention (EPR) effect (Veronese et al. 2008). The EPR effect describes the more 
open, or leaky, vasculature of tumor environments, which allows the permeation of 
larger molecules than normal tissue environments would allow (Greish et al. 2007).  
The poor lymphatic drainage of tumor environments allows retention of these 
molecules, increasing exposure time of the tumor environment to the conjugated 
chemotherapeutic (Greish et al. 2007).   
 
A common drug linkage is the covalent attachment of poly(ethylene glycol) (PEG), 
which increases a drug's water solubility, leading to an increase in drug dosage 
concentrations in normally hydrophobic chemotherapeutics such as doxorubicin 
(Veronese et al. 2008). However, PEGylation alone is not sufficient to reach the high 
level of drug loading required for increased therapeutic results.  A phosphorylcholine 
(MPC) polymer designed by Dr. Todd Emrick (University of Massachusetts Amherst 
Polymer Science Department), provides hydrophobic drugs like doxorubicin with 
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high water solubility as well as increased drug loading (Emrick Lab Data, 2010).  A 
poly(methacryloyloxyethyl phosphorylcholine) (polyMPC)-doxorubicin conjugate of 
Dr. Emrick's design has shown promise in its use as a chemotherapeutic conjugate 
(Emrick, 2011).  In vitro experiments show polyMPC-doxorubicin to be stable at a 
normal physiological pH of 7.4 and instable, releasing its drug payload, at a low pH 
indicative of tumor environments due to their release of lactic acid (Emrick Lab Data, 
2010; Gerweck et al., 2006). This indicates that polyMPC-doxorubicin may be 
appropriate for tumor site-specific release of doxorubicin.   
 
A polyMPC polymer offers several advantages over other polymers currently under 
investigation for chemotherapeutic delivery. Dendritic polymers, such as 
polyamidoamine (PAMAM) and polypropyleneimine, are widely investigated, but 
require surface modifications to avoid toxicity, while others, like polyaryl ether 
dendrimers, require modifications to increase water solubility (Gillies et al., 2005). In 
addition, the release of molecules can be difficult to control, not offering the 
controlled release desirable in drug delivery; along with low hydrodynamic size 
increases that do not allow utilization of the EPR effect (Jansen et al., 1995; 
Nishikawa et al, 1996). Other investigated polymers, such as N-(2-Hydroxypropyl) 
methacrylamide (HPMA), also carry risk of toxic accumulation. They are not 
biodegradable and can accumulate in the skin through the reticuloendothelial system 
(RES) (Duncan et al., 2010). The biggest drawback to both dendritic and HPMA 
polymers is the complicated synthesis required to create and modify these polymers. 
PolyMPC has a large advantage over these polymers in this regard, being synthesized 
in a simple one-pot method.  
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Protein therapeutics is another area of investigation for cancer treatment, along with 
other diseases such as Hepatitis C. Obstacles facing protein therapeutic treatment is 
high blood clearance times, preventing absorption and utilization of the proteins, 
degradation due to immune response, and protein aggregation (Mero et al, 2011). 
Polymers offer a way to circumvent the natural immune response by masking 
proteins, and conjugation aids in preventing protein aggregation. The increased 
circulation time afforded by Dr. Emrick’s phosphorylcholine methacrylate polymer 
over conventional PEGylated polymers makes it a good candidate for protein 
therapeutics.  
 
A third important area of investigation for both cancers and additional diseases, such 
as muscular dystrophy, is gene delivery. Efficient gene delivery is highly desirable, 
yet a continued obstacle for scientists. Gene delivery would allow scientists to correct 
altered gene expression, whether it be over-expression or lack of expression, which is 
responsible for disease progression, therefore providing a cure for the disease. 
Unfortunately, efficient gene delivery and incorporation has continued to elude 
scientists to date. Polymers offer a way to increase cellular uptake of plasmids and 
therefore increase the chances of plasmid incorporation and expression. An additional 
polymer designed by Dr. Emrick has the potential to increase cellular uptake and 
incorporation of DNA, while decreasing cell death (Parelkar et al., 2011). 
 
To further investigate their potential, polyMPC was tested in vivo for its maximum 
tolerated dose, cardio-toxicity, and biodistribution, MPC-protein polymers were tested 
in three different architectures for in vivo tissue toxicity, and a transfection polymer, 
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NLS2, was tested for its tissue toxicity and transfection efficiency into muscle.   
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Polymers and Chemotherapeutics 
The pMPC, pMPC-doxorubicin, and doxorubicin were kindly donated in powder 
form by the Emrick Laboratory, Polymer Science and Engineering Department, 
Univeristy of Massachusetts Amherst, stored at 4oC in the dark and kept dry. The 
powders were weighed, Hank’s Balanced Salt Solution (HBSS) was added, and the 
solutions vortexed until the powders were dissolved.  Once dissolved, the solutions 
were sterilized by filtration through a 0.2 µm pore filter and stored at 4oC until use. 
Doxil® was also provided by the Emrick Laboratory and stored at 4oC until use. 
NLS2 and JetPEI™ transfection polymers was provided by the Emrick Lab, stored at 
-20oC, combined with GFP plasmid, and incubated for 1 hour at room temperature 
immediately prior to injection. Protein therapeutic polymers (Lysozyme, linear MPC 
polymer, branched MPC polymer, and grafted MPC polymer) conjugated to Alexa 
Fluor® 546 (AF546) were supplied by the Emrick Lab and stored at -20oC until use.    
   
2.2 Animal Models 
Four to five-week old athymic nude mice (Nu/J) were purchased from Jackson 
Laboratories (Stock #002019) and housed and treated in accordance with the 
Institutional Animal Care and Use Committee. PolyMPC treatments were injected 
into the left or right lateral tail vein and blood was collected from the submandibular 
vein into 1.5 mL microcentrifuge tubes.  
C57BL/6J mice were purchased from Jackson Laboratories (Stock #000664) and used 
for both the protein polymer and transfection polymer experiments. Protein polymers 
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were injection into the tails of 6 week old mice, and blood was collected from the tails 
at 5, 10, 15, 30, 45, 60, and 120 minutes, 4, 6, 12, and 24 hours, and daily for 2 weeks 
following injection. Transfection polymers were injected into the right anterior tibialis 
muscle of 5 week old mice. 
   
2.3 Cell Lines 
MDA-MB-231 cells were cultured, either from previously frozen laboratory stocks or 
recently purchased from ATCC (Catalogue #HTB-26), in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS and 1:500 gentamicin (MDA-
medium). For in vivo experiments, cells were grown to ~80% confluence, harvested 
with trypsin in log phase, and suspended to a concentration of 1x105 cells/uL in 
HBSS. Cell suspensions were injected into the right flank of athymic nude mice at a 
total volume of 100 uL and 1x 107 cells. Tumor volume was calculated by 
L*W2*0.52.  
 
2.4 Blood and Tissue Handling 
Blood samples were allowed to clot on ice and then centrifuged at 1500 x g for 15 
minutes. PolyMPC serum samples were collected and stored at 4oC until analyzed for 
fluorescence excitation at 490 nm and emission at 590 nm, by high performance 
liquid chromatography (HPLC) by Xiangji Chen. Tissues were collected post-mortem 
and either fixed in 10% formalin for 24 hours at 4oC and paraffin embedded or frozen 
in liquid nitrogen and stored at -80oC.  Frozen tissues were weighed and then 
homogenized in acidified isopropanol (90% isopropanol, 75mM HCL) and incubated 
overnight at 4oC, followed by centrifugation at 1500 x g for 15 minutes. The liquid 
supernatant was collected and stored at 4oC until analyzed for fluorescence excitation 
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at 490 nm and emission at 590 nm, by HPLC by Xiangji Chen.  Paraffin embedded 
tissues were treated with hemotoxylin and eosin (H&E) stain and analyzed for tissue 
architecture and cell staining patterns, or analyzed for apoptotic cells by TUNEL 
using ApopTag® Plus Peroxidase In Situ Apoptosis Kit according to the provided 
protocol.  
At the end of 2 weeks protein polymer mice were euthanized and spleens, kidneys, 
intestines, livers, lungs, and hearts were collected, weighed, and homogenized in 
1XPBS. Tissue homogenates were centrifuged at 4oC at 1500 x g for 15 minutes and 
stored at -20oC until analyzed for fluorescence by HPLC. 
Transfection polymer tissues were collected after 4 weeks, fixed in 10% formalin for 
24 hours at 4oC and paraffin embedded for sectioning. Tissue sections were treated 
with GFP antibody and analyzed for positive staining or H&E stain and analyzed for 
tissue architecture and cell staining patterns.  
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CHAPTER 3 
RESULTS 
 
3.1 Maximum Tolerated Dose of polyMPC-Doxorubicin 
PolyMPC-drug conjugates containing 30% doxorubicin by weight were tested in 
doxorubicin doses of 10, 20, 30, 40, and 50 mg of doxorubicin per kg of body weight 
to determine the maximum dose administrable without eliciting adverse effects. Seven 
week old animals, three mice per group, received a single, intravenous injection in the 
lateral tail vein of polyMPC-dox, polyMPC alone, or Hank's Balanced Salt Solution 
(HBSS). The animals were weighed and examined daily for 30 days. Figure 1 shows 
the weight changes in mice following treatment. A slight decrease in weight was 
observed at day five in 30, 40, and 50 mg/kg dose groups, and shows that a single 
injection at that dose may elicit some toxicity; however the mice were able to recover 
from such toxicity, indicated by the return to normal weight ranges by day 24.  
Necrosis around the injection site was observed these doses, most likely caused by 
extravascular drug administration, and is the likely cause of the weight changes 
observed in these mice. The results indicate that polyMPC can be used to increase the 
concentration of doxorubicin without eliciting irreversible side effects. 
 
PolyMPC drug conjugates were then compared to doses of free doxorubicin and 
Doxil®, a commercially available liposome form of doxorubicin, in ten mice per 
treatment group. Free doxorubicin was administered at a concentration of 6 mg/kg 
and Doxil® was administered at a concentration of 10 mg/kg. A dose of 30 mg/kg 
polyMPC-doxorubicin was chosen as that was the highest doxorubicin concentration 
with the least observed toxicity in the previous experiment. Doxil®, polyMPC-
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doxorubicin, and HBSS were administered on day 0 and day 7, for a total doxorubicin 
dose of 20 mg/kg in Doxil® and 60 mg/kg in polyMPC-doxorubicin; however free 
doxorubicin was only administered on day 0 due to observed toxicity prior to and on 
day 7 of treatment. The animals were weighed and examined daily for up to 54 days 
(Figure 2).  The results indicate that polyMPC-doxorubicin can be given at three times 
the doxorubicin dose in Doxil®, and ten times the dose of free doxorubicin, while 
exhibiting less toxicity-induced weight loss. On day 55, or upon presentation of 
toxicity, hearts were collected, fixed in 10% formalin, and paraffin embedded. Tissue 
sections were first analyzed for apoptotic cells by TUNEL (Figure 3). No apoptotic 
were observed in these tissues. Due to lack of apoptotic cells present, cardiac tissues 
were then treated with hematoxylin and eosin stain. Under 40x magnification, the 
stained nuclei were counted per field of vision. The hearts of mice treated with free 
doxorubicin show less nuclear staining per 40x field than the hearts of mice treated 
with either HBSS, Doxil®, or polyMPC-doxorubicin (Figure 4 & 5). While actively 
occurring death was not observed, likely due to the length of time following injection, 
there seems to have been a loss of muscle cells due to doxorubicin, which was 
prevented by conjugation to the polymers. These results provide evidence of the 
decreased toxicity with increased drug dosage provided by polyMPC-doxorubicin.    
 
3.2 Biodistribution and Clearance of polyMPC-Doxorubicin 
The effect of polymer conjugation on the clearance of doxorubicin in animal serum 
was tested on five-week old female athymic nude mice.  The mice were divided 
randomly into three groups and injected intravenously through the tail vein with 
polyMPC-doxorubicin or free doxorubicin at 6 mg/kg, or with HBSS of the same 
volume. Blood samples of 30-50 uL were taken at 0, 30 minutes, 2 hours, 6 hours, 12 
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hours, 24 hours, 48 hours, and 72 hours post-treatment and analyzed for doxorubicin 
fluorescence by HPLC. The results (Figure 6) indicate that polyMPC-doxorubicin has 
a longer blood circulation time than that of free doxorubicin.  
 
To examine the biodistribution of polyMPC-doxorubicin in comparison to free 
doxorubicin, kidneys, livers, and hearts were collected after 72 hours from the mice 
used for the clearance experiment and analyzed for doxorubicin fluorescence by 
HPLC. The results (Figure 7) indicate there may have been accumulation of 
polyMPC-doxorubicin in the liver and kidney to a greater extent than free 
doxorubicin, although the variation between animals was considerably large and there 
was no statistical difference in accumulation. In addition, H&E staining of livers did 
not show any discernable differences in tissue architecture (Figure 8).      
   
To observe tumor accumulation of polyMPC-doxorubicin versus free doxorubicin, 
MDA-MB-231 cells were harvested with trypsin in log phase and suspended in HBSS 
at a concentration of 1x107 / 100uL and injected into the right flank of six week old 
athymic nude mice.  Once the tumors reached a volume of 300-500 mm3, mice were 
divided randomly into three groups of 2 mice and injected intravenously through the 
tail vein with polyMPC-doxorubicin or free doxorubicin at 6 mg/kg, or with HBSS of 
the same volume.  At 12 hours and 24 hours post-treatment, the tumors were 
collected, homogenized in acidified isopropanol, and analyzed for doxorubicin 
fluorescence by HPLC (Figure 9). However, tumors did not grow in the majority of 
mice injected with MDA-MB-231 cells, and though these results indicate that 
polyMPC does not increase doxorubicin accumulation in the tumor, there was only 
one mouse per group and no significant information can be obtained from this data. 
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3.3 MPC-AF546 Affect on Tissue Weight 
Six week old C57BLK/6J mice were injected into the tail with Lysozyme-AF546, 
Linear MPC-AF546, Branched MPC-AF546, or Grafted MPC-AF546. Blood samples 
and tissue homogenates were stored at -20oC for future HPLC analysis for AF546 
fluorescence.  Prior to homogenization, tissues were weighed, and tissue weights were 
compared to see if there was statistical differences in tissue weight that may indicate 
toxicity. When compared (Figure 10), there was a significant decrease in lung tissue 
weight in the grafted polymer group compared to the PBS control (P=0.0038), 
however there was no significant difference between tissue weights for the other 
groups or tissues. This decrease in tissue weight may indicate an accumulation and 
resultant toxicity of the grafted polymer in the lungs.    
 
3.4 NSL2 Muscle Transfection 
Five week old C57BLK/6J were injected with 10 uL into the proximal portion of the 
anterior tibialis muscle, and 10 uL into the distal portion of the anterior tibialis 
muscle, of either PBS, pEGFP, Jet-PEI-pEGFP (a commercially available linear 
polyethylenimine tranfection reagent), or NLS2-pEGFP.  Four weeks following 
injection, the anterior tibialis muscles were collected, fixed in 10% formalin, and 
paraffin embedded. Tissue sections were then treated with GFP antibody to determine 
protein expression and transfection efficiency. There was not positive GFP staining 
observed in any of the tissue sections (Figure 11). Sections were then stained with 
hematoxylin and eosin for tissue architecture (Figure 12). The H&E staining indicates 
there is no difference in tissue architecture between treatment groups, indicating that 
NLS2 does not cause tissue toxicity upon direct injection into the muscle. 
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CHAPTER 4 
DISCUSSION & FUTURE DIRECTIONS 
 
By conjugating doxorubicin to polyMPC, the maximum tolerated dose in mice is 
increased by ten-fold over free doxorubicin and three-fold over Doxil®. Though some 
weight loss was observed in mice, this was most likely due to experimenter error in 
administration, not a cause of the polyMPC-doxorubicin, and recovery was observed 
with return to normal weight ranges. In addition, the cardio-toxicity normally 
associated with free doxorubicin treatment is circumvented through its conjugation to 
polyMPC as evidenced through nuclear staining, and is presumably the cause of the 
increase in the maximum tolerated dose in mice. The conjugation of doxorubicin to 
polyMPC also increases the blood circulation time of doxorubicin, providing 
increased exposure time of the drug with a reduced toxicity. We were not able to 
demonstrate an accumulation of polyMPC-doxorubicin inside the tumor, however, as 
there were not enough models to determine a lack of accumulation outside of 
circumstance. Due to difficulty in growing the MDA-MB-231 xenografts, it is 
possible that an unusual tumor environment was established that deviates in a way to 
exclude the polyMPC-doxorubicin which would be effective in a normally formed 
MDA-MB-231 xenograft. There was trend of increased accumulation of polyMPC in 
the liver and kidneys, however not to a statistically significant amount, and it is 
possible that this observation was the result of normal excretion of the drug conjugate, 
and not extratumoral release of doxorubicin from the polymer. Because the tissues 
were homogenized in acidified isopropanol to release doxorubicin from the polymer 
for analysis, it is not possible to determine if the accumulated doxorubicin was free to 
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elicit toxicity in these organs, or if it was still polymer bound and inactive.  Since 
there was no evidence of toxicity in these tissues, it is likely that the doxorubicin was 
still conjugated and inactive.      
 
The MPC-AF546 polymers showed varying results in tissue weights based on the 
architecture of the polymers administered, however additional analysis of polymer 
accumulation in tissues would need to be investigated before conclusions could be 
drawn from this data. If polymer accumulation coincides with reduced tissue weight, 
it is possible that the polymer is causing tissue toxicity and tissues should be 
investigated for apoptosis and altered architecture. 
 
NSL2 was shown not to cause toxicity when injected into the muscle; however 
transfection of the pEGFP was also not demonstrated. This may be due to the length 
of time from injection to tissue collection, and not an indication of failed transfection 
as there was also no positive GFP staining from the JetPEI™ control.  
 
In future, polyMPC-doxorubicin will be tested in vivo for tumor accumulation and 
treatment efficacy on MDA-MB-231 xenografts to demonstrate its increased efficacy 
over doxorubicin and Doxil® treatment. Serum samples and tissues from MPC-AF546 
treated mice will be analyzed by HPLC to determine blood clearance times and tissue 
accumulation of the various architectural forms of the polymer to determine its 
efficacy in protein therapeutics. NSL2 will be tested in highly proliferative cell 
environments, such as tumor and mammary tissues, to determine its transformation 
efficiency, as well as being tested in varying polymer:DNA ratios to improve 
transformation efficiency.   
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Figure 1 Mouse Weights Following PolyMPC-Doxorubicin Treatment  
Three mice per group were injected with 10, 20, 30, 40, or 50 mg of doxorubicin per 
kg of body weight, or HBSS or empty polyMPC as controls. Mice were weighed and 
examined for toxicity daily for 30 days. Daily mouse weights were averaged for each 
group (n=3) and graphed above.
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Figure 2 Mouse Weights Following Doxorubicin Treatment 
Ten mice per group were injected with the maximum tolerated dose of free 
doxorubicin (6mg/kg), Doxil® (liposomal doxorubicin, 10 mg/kg), polyMPC-
doxorubicin (30 mg/kg), or HBSS as a control. Mice were weighed and examined for 
toxicity 2 times a week for 54 days. Weights were averaged (starting n=10) and 
graphed above. Six mice were lost from the free doxorubicin group during the course 
of the experiment (ending n=4), 3 mice were lost from the polyMPC-doxorubicin 
group (ending n=7), 2 mice were lost from the Doxil® group (ending n=8), and 1 
mouse was lost from the HBSS group (ending n=9). 
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Figure 3 TUNEL Treated Cardiac Tissue of Doxorubicin Treated Mice 
Ten mice per group (n=10) were injected with the maximum tolerated dose of free 
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or 
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were 
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then 
labeled with TUNEL for apoptotic cell identification. Positive staining for apoptotic 
cells was not observed.  
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Figure 4 Hematoxylin and Eosin Stained Cardiac Tissue of Doxorubicin Treated Mice 
Ten mice per group (n=10) were injected with the maximum tolerated dose of free 
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or 
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were 
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then 
treated with hematoxylin and eosin stain to reveal tissue architecture and cell staining 
patterns.  
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Figure 5 Number of Eosin Stained Nuclei per 40x Field of Vision 
Ten mice per group were injected with the maximum tolerated dose of free 
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or 
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were 
collected, fixed in 10% formalin, paraffin embedded, and treated with hematoxylin 
and eosin stain. Images were collected under 40x magnification bright field 
microscopy and the total numbers of nuclei in each image were counted and averaged 
per group (n=10). There was a statistically significant decrease (P<0.0001) in nuclei 
in cardiac tissue collected from free doxorubicin treated mice.
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Figure 6 Blood Clearance of PolyMPC-Doxorubicin 
Five mice were injected into the tail vein with 6mg/kg of free doxorubicin (n=5), and 
six mice were injected into the tail vein with 6 mg/kg of polyMPC-doxorubicin (n=6). 
Blood samples were taken at 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours, 48 
hours, and 72 hours post-injection. Serum was collected from the blood and analyzed 
by HPLC for doxorubicin fluorescence. By 6 hours post-injection, over 93% of free 
doxorubicin has been eliminated from serum, and doxorubicin levels are not 
detectable past 48 hours post-injection. At 6 hours post-injection, 40% of PolyMPC-
doxorubicin is still present in serum and levels remain detectable at 72 hours post-
injection. 
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Figure 7 Tissue Accumulation of PolyMPC-Doxorubicin 
Five mice were injected into the tail vein with 6mg/kg of free doxorubicin (n=5), and 
six mice were injected into the tail vein with 6 mg/kg of polyMPC-doxorubicin (n=6). 
Tissues were collected following 72 hours of treatment, frozen in liquid nitrogen, and 
tissue homogenates were analyzed by HPLC for doxorubicin fluorescence. 
Differences in doxorubicin fluorescence in tissues are not statistically significant 
between treatment groups.  
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Figure 8 Hematoxylin and Eosin Stained Hepatic Tissue of Doxorubicin Treated Mice 
Ten mice per group (n=10) were injected with the maximum tolerated dose of free 
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or 
HBSS as a control. Following 54 days, or presentation of toxicity, livers were 
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then 
treated with hematoxylin and eosin stain to reveal tissue architecture and cell staining 
patterns.  
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Figure 9 Tumor Accumulation of PolyMPC-Doxorubicin 
MDA-MB-231 xenografts were grown in the right flank of six mice to a tumor 
volume of 100-300 mm3. Mice were then injected into the tail with 6mg/kg free 
doxorubicin or polyMPC-doxorubicin, or HBSS as a control. At 12 or 24 hours post-
injection, tumors were collected (n=1) and analyzed by HPLC for doxorubicin 
fluorescence. 
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Figure 10 Tissue Weights of Lysozyme Treated Mice 
Mice were injected into the tail with three architectural forms of MPC-AF546, or 
lysozyme-AF546 or PBS as control. Two weeks following treatment, tissues were 
collected and weighed (n=6). Lungs of mice treated with grafted MPC-AF546 
weighed statistically less than lungs of mice treated with PBS (P=0.0038). 
All other tissues were not statistically different weights.  
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Figure 11 GFP Antibody Staining of Anterior Tibialis Muscles 
 Mice were injected with 10uL into the proximal anterior tibialis muscle, and 10uL 
into the distal anterior tibialis muscle, on day 0 and day 7. Tissues were collected 4 
weeks post-injection, fixed in formalin, and paraffin embedded. Tissue sections were 
treated with anti-GFP antibody. No positive antibody staining was observed.  
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Figure 12 Hematoxylin and Eosin Stained Tibialis Muscles  
Mice were injected with 10uL into the proximal anterior tibialis muscle, and 10uL 
into the distal anterior tibialis muscle, on day 0 and day 7. Tissues were collected 4 
weeks post-injection, fixed in formalin, and paraffin embedded. Tissue sections were 
treated with hematoxylin and eosin stain. No differences in tissue architecture were 
observed. 
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